Regadenoson

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ischemic Heart Disease

Conditions

Ischemic Heart Disease

Trial Timeline

Jun 1, 2009 → Dec 1, 2011

NCT ID

NCT00881218

About Regadenoson

Regadenoson is a phase 1 stage product being developed by Astellas Pharma for Ischemic Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00881218. Target conditions include Ischemic Heart Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02697877	Pre-clinical	Completed	Feb 1, 2016	Jul 1, 2018	Coronary Artery Disease
NCT02589977	Approved	Completed	Nov 1, 2015	Jan 21, 2020	Heart Failure, Diastolic
NCT02220634	Pre-clinical	Terminated	Aug 1, 2014	May 25, 2017	Pulmonary Hypertension
NCT01969916	Pre-clinical	Completed	Jun 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01779869	Approved	Completed	Jan 1, 2013	Jun 1, 2015	Ischemic Heart Disease
NCT01618669	Phase 3	Completed	Jun 1, 2012	Dec 1, 2014	Coronary Artery Disease (CAD)
NCT01446094	Approved	UNKNOWN	Aug 1, 2011	Jun 1, 2018	Coronary Artery Disease
NCT01334918	Phase 2	Completed	Apr 26, 2011	Jul 2, 2012	Coronary Artery Disease (CAD)
NCT01021618	Pre-clinical	Completed	Jan 1, 2010	Mar 1, 2012	Coronary Artery Disease
NCT01026012	Pre-clinical	Completed	Dec 1, 2009	Sep 1, 2010	Cardiac Function
NCT00881218	Phase 1	Completed	Jun 1, 2009	Dec 1, 2011	Ischemic Heart Disease
NCT00837369	Phase 1	Completed	Apr 7, 2009	Dec 1, 2011	Coronary Artery Disease
NCT00871260	Approved	Completed	Apr 1, 2009	Jun 4, 2014	Coronary Disease
NCT00857792	Pre-clinical	Completed	Mar 1, 2009	Jan 1, 2013	Coronary Disease

Competing Products

20 competing products in Ischemic Heart Disease

See all competitors

Product	Company	Stage	Hype Score
Aspirin, Clopidogrel	Yuhan	Pre-clinical	23
DS-1040b + Placebo	Daiichi Sankyo	Phase 1/2	41
DS-1040b + Aspirin	Daiichi Sankyo	Phase 1	33
DS1040b + Placebo	Daiichi Sankyo	Pre-clinical	23
Pharmacological intensification based on olmesartan	Daiichi Sankyo	Phase 2	52
YM872 (zonampanel), t-PA (alteplase)	Astellas Pharma	Phase 2	52
Regadenoson	Astellas Pharma	Approved	85
ASP2246	Astellas Pharma	Phase 1/2	41
Gadolinium + Adenosine	Astellas Pharma	Phase 2/3	65
XY03-EA + XY03-EA Placebo	Sun Pharmaceutical	Phase 2	52
Redasemtide + Placebo	Shionogi	Phase 2	52
Statin	Shionogi	Approved	85
fospropofol + propofol	Eisai	Phase 2	52
PDE5 Inhibitors	Eli Lilly	Pre-clinical	23
SB623 Implant (2.5M) + SB623 Implant (5.0M)	Sumitomo Pharma	Phase 2	52
Mesenchymal stem cell + Placebo	Rohto Pharmaceutical	Phase 2	52
Elezanumab + Placebo	AbbVie	Phase 2	52
Balovaptan + Placebo	Roche	Phase 2	52
Repatha	Amgen	Approved	84
GS-6615 + Placebo	Gilead Sciences	Phase 1	32

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved